Free Trial

Personalis, Inc. (NASDAQ:PSNL) Stock Now Rated "Hold" by Sell-Side Brokerages

Personalis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is mostly neutral: Of 10 analysts covering Personalis, seven rate it Hold, two Buy and one Sell; the average 12-month price target is $15.29.
  • Quarterly results were mixed: Personalis reported a loss of $0.32 per share, missing estimates of $0.26, while revenue of $25.6 million exceeded expectations of $21.54 million.
  • Institutional ownership stands at 61.91%, with several major investors recently acquiring or adding shares. Recent insider sales were made to cover tax withholding on vested equity awards.
  • Five stocks we like better than Personalis.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has earned an average rating of "Hold" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.29.

A number of equities analysts recently weighed in on PSNL shares. Zacks Research raised Personalis from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. Needham & Company LLC downgraded Personalis from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a report on Thursday, October 15th. Lake Street Capital cut Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a research report on Monday, July 20th. Finally, UBS Group downgraded Personalis from a "buy" rating to a "neutral" rating in a research note on Tuesday, October 6th.

Get Our Latest Research Report on PSNL

Insider Activity at Personalis

In other Personalis news, SVP Stephen Moore sold 2,068 shares of the company's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the transaction, the senior vice president directly owned 90,257 shares in the company, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Richard Chen sold 3,998 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the transaction, the chief marketing officer directly owned 169,882 shares in the company, valued at approximately $2,755,486.04. The trade was a 2.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,456 shares of company stock worth $266,916 over the last 90 days. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Personalis

Several large investors have recently bought and sold shares of PSNL. Merck & Co. Inc. acquired a new position in Personalis in the 2nd quarter valued at $188,202,236. BlackRock Inc. acquired a new stake in Personalis during the 2nd quarter worth $94,905,000. Aberdeen Group plc boosted its stake in Personalis by 39.1% during the 3rd quarter. Aberdeen Group plc now owns 5,211,939 shares of the company's stock worth $84,850,000 after purchasing an additional 1,464,649 shares during the last quarter. Bank of America Corp DE acquired a new stake in Personalis during the 2nd quarter worth $24,395,000. Finally, AIGH Capital Management LLC purchased a new stake in shares of Personalis during the second quarter worth $22,981,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $15.71 on Monday. Personalis has a 12-month low of $4.95 and a 12-month high of $18.89. The company has a market capitalization of $1.70 billion, a PE ratio of -13.43 and a beta of 2.40. The business has a 50 day moving average of $16.08 and a two-hundred day moving average of $11.61.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The firm had revenue of $25.60 million during the quarter, compared to analysts' expectations of $21.54 million. Personalis had a negative net margin of 147.74% and a negative return on equity of 49.53%.

About Personalis

(Get Free Report)

Personalis is a cancer genomics company that develops sequencing and data-analysis tools for cancer research and personalized cancer care. Its services support pharmaceutical and biotechnology companies, academic researchers, and clinicians studying cancer and evaluating treatments. The company's offerings include NeXT Personal, a blood-based test designed to detect molecular residual disease and monitor cancer recurrence using circulating tumor DNA. Personalis also provides tumor profiling and immunogenomics services that analyze cancer-related genetic changes and features of the tumor immune environment.

Further Reading

Analyst Recommendations for Personalis (NASDAQ:PSNL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Personalis Right Now?

Before you consider Personalis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.

While Personalis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines